Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 2
2023 2
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Ketamine for depression.
Jelen LA, Stone JM. Jelen LA, et al. Int Rev Psychiatry. 2021 May;33(3):207-228. doi: 10.1080/09540261.2020.1854194. Epub 2021 Feb 11. Int Rev Psychiatry. 2021. PMID: 33569971 Review.
Ketamine is a racemic mixture composed of equal amounts of (S)-ketamine and (R)-ketamine. Although ketamine currently remains an off-label treatment for TRD, an (S)-ketamine nasal spray has been approved for use in TR …
Ketamine is a racemic mixture composed of equal amounts of (S)-ketamine and (R)-ketamine. Although ketamine …
Ketamine: A tale of two enantiomers.
Jelen LA, Young AH, Stone JM. Jelen LA, et al. J Psychopharmacol. 2021 Feb;35(2):109-123. doi: 10.1177/0269881120959644. Epub 2020 Nov 6. J Psychopharmacol. 2021. PMID: 33155503 Free PMC article. Review.
Ketamine is a racemic mixture, composed of equal amounts of (S)-ketamine and (R)-ketamine. An (S)-ketamine nasal spray has been developed and approved for use in treatment-resistant depression in the United States and Europe …
Ketamine is a racemic mixture, composed of equal amounts of (S)-ketamine and (R)-ketamine. An (S)-keta …
Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study.
Zaki N, Chen LN, Lane R, Doherty T, Drevets WC, Morrison RL, Sanacora G, Wilkinson ST, Popova V, Fu DJ. Zaki N, et al. Neuropsychopharmacology. 2023 Jul;48(8):1225-1233. doi: 10.1038/s41386-023-01577-5. Epub 2023 May 12. Neuropsychopharmacology. 2023. PMID: 37173512 Free PMC article. Clinical Trial.
Patients with treatment-resistant depression (TRD) have higher rates of relapse and pronounced decreases in daily functioning and health-related quality of life compared to patients with major depressive disorder who are not treatment-resistant, underscoring the need for treatmen …
Patients with treatment-resistant depression (TRD) have higher rates of relapse and pronounced decreases in daily functioning and health-rel …
Changing the paradigm in treatment-resistant depression: A review of long-term efficacy and tolerability of esketamine nasal spray.
Herrera-Imbroda J. Herrera-Imbroda J. Exp Clin Psychopharmacol. 2023 Dec;31(6):1092-1101. doi: 10.1037/pha0000650. Epub 2023 May 1. Exp Clin Psychopharmacol. 2023. PMID: 37126036 Review.
We consider in this review whether this therapy is also safe and effective in the long-term treatment of patients. A narrative review, using a comprehensive Pubmed search, and other search strategies, of long-term studies evaluating the safety and efficacy of esk …
We consider in this review whether this therapy is also safe and effective in the long-term treatment of patients. A narrative review …
Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial report.
Conway CR, Rush AJ, Aaronson ST, Bunker MT, Gordon C, George MS, Riva-Posse P, Allen RM, Nahas Z, Kriedt CL, Zajecka J, Dunner DL, Quevedo J, Sheline Y, Duffy W, Mickey BJ, Stedman M, Alva G, Manu L, Tran Q, Zorumski CF, Macaluso M, Banov M, Cusin C, Bennett JI, Brown H, Way J, Shy O, Lee YL, McAllister-Williams RH, McIntyre RS, Sackeim HA. Conway CR, et al. Int J Neuropsychopharmacol. 2026 Jan 6;29(1):pyaf080. doi: 10.1093/ijnp/pyaf080. Int J Neuropsychopharmacol. 2026. PMID: 41529263 Free PMC article. Clinical Trial.
DESIGN: Prospective, open-label, single-arm, long-term extension study (RECOVER) conducted from September 2019 to April 2025. SETTING: Outpatient. ...INTERVENTIONS: Vagus nerve stimulation and concomitant psychotropic medications and interventional psychiatric modalities ( …
DESIGN: Prospective, open-label, single-arm, long-term extension study (RECOVER) conducted from September 2019 to April 2025. SETTING …